|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hendriks LE, Kerr KM, Menis J, Mok TS,
Nestle U, Passaro A, Peters S, Planchard D, Smit EF, Solomon BJ, et
al: Non-oncogene addicted metastatic non-small-cell lung cancer:
ESMO Clinical Practice Guideline for diagnosis, treatment and
follow-up. Ann Oncol. 34:358–376. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Leone GM, Candido S, Lavoro A, Vivarelli
S, Gattuso G, Calina D, Libra M and Falzone L: Clinical relevance
of targeted therapy and immune-checkpoint inhibition in lung
cancer. Pharmaceutics. 15:12522023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jurisic V, Vukovic V, Obradovic J,
Gulyaeva LF, Kushlinskii NE and Djordjević N: EGFR polymorphism and
survival of NSCLC patients treated with TKIs: A systematic review
and meta-analysis. J Oncol. 2020:19732412020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Obradovic J, Todosijevic J and Jurisic V:
Side effects of tyrosine kinase inhibitors therapy in patients with
non-small cell lung cancer and associations with EGFR
polymorphisms: A systematic review and meta-analysis. Oncol Lett.
25:622022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Everest L, Shah M and Chan KKW: Comparison
of long-term survival benefits in trials of immune checkpoint
inhibitor vs. Non-immune checkpoint inhibitor anticancer agents
using ASCO value framework and ESMO magnitude of clinical benefit
scale. JAMA Netw Open. 2:e1968032019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Falzone L, Bordonaro R and Libra M:
SnapShot: Cancer chemotherapy. Cell. 186:1816.e12023. View Article : Google Scholar
|
|
8
|
Ettinger DS, Wood DE, Aisner DL, Akerley
W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico
TA, et al: Non-Small cell lung cancer, version 3.2022, NCCN
clinical practice guidelines in oncology. J Natl Compr Canc Netw.
20:497–530. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bironzo P and Di Maio M: A review of
guidelines for lung cancer. J Thorac Dis. 10 (Suppl
13):S1556–S1563. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hanna N, Johnson D, Temin S, Baker S Jr,
Brahmer J, Ellis PM, Giaccone G, Hesketh PJ, Jaiyesimi I, Leighl
NB, et al: Systemic therapy for stage IV Non-small-cell lung
cancer: American Society of Clinical Oncology Clinical Practice
Guideline Update. J Clin Oncol. 35:3484–3515. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li C, Qiu Y and Zhang Y: Research progress
on therapeutic targeting of cancer-associated fibroblasts to tackle
treatment-resistant NSCLC. Pharmaceuticals (Basel). 15:14112022.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Leonetti A, Sharma S, Minari R, Perego P,
Giovannetti E and Tiseo M: Resistance mechanisms to osimertinib in
EGFR-mutated non-small cell lung cancer. Brit J Cancer.
121:725–737. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee KWC, Li MSC, Gai W, Lau YM, Chan AKC,
Chan OSH, Lee CK, Yeung RMW, Fung SYH, Cheung WF, et al: Testing
for EGFR variants in pleural and pericardial effusion cell-free DNA
in patients with non-small cell lung cancer. JAMA Oncol. 9:261–265.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Patsoukis N, Wang Q, Strauss L and
Boussiotis VA: Revisiting the PD-1 pathway. Sci Adv.
6:eabd27122020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang Z, Yang N, Ou Q, Xiang Y, Jiang T, Wu
X, Bao H, Tong X, Wang X, Shao YW, et al: Investigating novel
resistance mechanisms to third-generation EGFR tyrosine kinase
inhibitor osimertinib in non-small cell lung cancer patients. Clin
Cancer Res. 24:3097–3107. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shu Y, Wu X, Tong X, Wang X, Chang Z, Mao
Y, Chen X, Sun J, Wang Z, Hong Z, et al: Circulating tumor DNA
mutation profiling by targeted next generation sequencing provides
guidance for personalized treatments in multiple cancer types. Sci
Rep. 7:5832017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu S, Sagiv O, Rubin ML, Sa HS, Tetzlaff
MT, Nagarajan P, Ning J and Esmaeli B: Validation Study of the AJCC
Cancer Staging Manual, Eighth Edition, Staging System for eyelid
and periocular squamous cell carcinoma. JAMA Ophthalmol.
137:537–542. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou Q and Wu YL: Developing CSCO lung
cancer practice guidelines stratified by resource availability and
treatment value. J Glob Oncol. 3:285–288. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang CY, Yeh YC, Wang LC, Lin YY, Lin SY,
Wang SY, Chu PY, Liu ZY, Su YC, Ho HL and Chou TY: Genomic
profiling with large-scale next-generation sequencing panels
distinguishes separate primary lung adenocarcinomas from
intrapulmonary metastases. Mod Pathol. 36:1000472023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Song X, Xiong A, Wu F, Li X, Wang J, Jiang
T, Chen P, Zhang X, Zhao Z, Liu H, et al: Spatial multi-omics
revealed the impact of tumor ecosystem heterogeneity on
immunotherapy efficacy in patients with advanced non-small cell
lung cancer treated with bispecific antibody. J Immunother Cancer.
11:e0062342023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Villaruz LC, Blumenschein GR Jr, Otterson
GA and Leal TA: Emerging therapeutic strategies for enhancing
sensitivity and countering resistance to programmed cell death
protein 1 or programmed death-ligand 1 inhibitors in non-small cell
lung cancer. Cancer. 129:1319–1350. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang
JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, et al: Gefitinib plus
chemotherapy versus chemotherapy in epidermal growth factor
receptor mutation-positive non-small-cell lung cancer resistant to
first-line gefitinib (IMPRESS): Overall survival and biomarker
analyses. J Clin Oncol. 35:4027–4034. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
He Y and An T: Toripalimab in an advanced
non-small cell lung cancer patient with poor general condition
after multiline treatment: A case report. J Int Med Res.
49:30006052110429882021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou J, Zhou F, Xie H, Wu Y, Zhao J and Su
C: An advanced non-small cell lung cancer patient with epidermal
growth factor receptor sensitizing mutation responded to
toripalimab in combination with chemotherapy after resistance to
osimertinib: A case report. Transl Lung Cancer Res. 9:354–359.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jiang T, Wang P, Zhang J, Zhao Y, Zhou J,
Fan Y, Shu Y, Liu X, Zhang H, He J, et al: Toripalimab plus
chemotherapy as second-line treatment in previously EGFR-TKI
treated patients with EGFR-mutant-advanced NSCLC: A multicenter
phase-II trial. Signal Transduct Target Ther. 6:3552021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang J, Wang Z, Wu L, Li B, Cheng Y, Li X,
Wang X, Han L, Wu X, Fan Y, et al: MA13.08 CHOICE-01: A Phase 3
study of toripalimab versus placebo in combination with first-line
chemotherapy for advanced NSCLC. J Thorac Oncol. 16:S927–S928.
2021. View Article : Google Scholar
|
|
27
|
Jurisic V, Radenkovic S and Konjevic G:
The actual role of LDH as tumor marker, biochemical and clinical
aspects. Adv Exp Med Biol. 867:115–124. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang Y, Lou Y, Wang J, Yu C and Shen W:
Research status and molecular mechanism of the traditional chinese
medicine and antitumor therapy combined strategy based on tumor
microenvironment. Front Immunol. 11:6097052021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Br Cassileth KS and Yeung: Supportive
Cancer Care with Chinese Medicine. Focus on Alternative and
Complementary Therapies. 15:261–262. 2010. View Article : Google Scholar
|
|
30
|
Sang T, Qiu W, Li W and Zhou H, Chen H and
Zhou H: The Relationship between prevention and treatment of
colorectal cancer and cancerous toxin pathogenesis theory basing on
gut microbiota. Evid Based Complement Alternat Med.
2020:71625452020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang S, Fu Jl, Hao Hf, Jiao YN, Li PP and
Han SY: Metabolic reprogramming by traditional Chinese medicine and
its role in effective cancer therapy. Pharmacol Res.
170:1057282021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fan D: Holistic integrative medicine:
Toward a new era of medical advancement. Front Med. 11:152–159.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang L, Gong Y, Zhang L, Liang B, Xu H,
Hu W, Jin Z, Wu X, Chen X, Li M, et al: Gou Qi Zi inhibits
proliferation and induces apoptosis through the PI3K/AKT1 signaling
pathway in non-small cell lung cancer. Front Oncol. 12:10347502022.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu P, Zhao Q, Xu Y, Ye J, Tan J, Hou J,
Wang Y, Li J, Cui W, Wang S and Wang X: A Chinese classical
prescription Qianjinweijing Decoction in treatment of lung cancer:
An overview. Biomed Pharmacother. 156:1139132022. View Article : Google Scholar : PubMed/NCBI
|
